| 名稱 | GSK484 hydrochloride |
| 描述 | GSK484 hydrochloride (GTPL8577) is a reversible peptidyl-arginine deiminase 4 (PAD4) inhibitor. It binds to PAD4 with high affinity, with IC50 of 250 and 50 nM in the presence and absence of 2 mM calcium, respectively. GSK484 promotes the radiosensitivity of colorectal cancer (CRC) and inhibits NET formation in vitro and in vivo. |
| 細胞實驗 | HEK293 cells stably expressing N-terminal FLAG-tagged PAD1, PAD2, PAD3 or PAD4 are engineered by retroviral transduction. Cells are grown in 15 cm diameter plates to subconfluency in DMEM supplemented with 10% Foetal Bovine Serum, harvested by centrifugation and washed once in PBS/2 mM EGTA. Cells are lysed in 50 mM Tris-Cl, pH 7.4, 1.5 mM MgCl2, 5% glycerol, 150 mM NaCl, 25 mM NaF, 1 mM Na3VO4, 0.4% NP40, 1 mM DTT with protease inhibitors. Lysates are pre-incubated for 20 min at 4°C with DMSO alone (2%), 100 μM of GSK199, GSK484, GSK106 or 200 μM Cl-amidine. Citrullination reactions are performed for 30 min at 37°C in the presence of 2 mM calcium. Extracts are loaded on to gels, proteins separated by SDS-PAGE and transferred to PVDF membranes. Citrullinated proteins are then chemically modified and detected using an anti-modified citrulline antibody. FLAG-PAD constructs are detected using the anti-FLAG antibody [1]. |
| 激酶實驗 | PAD4 is serially diluted in the presence of 10 nM GSK215 in assay buffer (100 mM HEPES, pH 8, 50 mM NaCl, 5% glycerol, 1 mM CHAPS, 1 mM DTT) at varying concentrations of calcium (0, 0.2, 2 and 10 mM). Following incubation for 50 min, apparent Kds for each calcium concentration are determined using a single site saturation curve. For IC50 determination, GSK484 is serially diluted in DMSO (1% final assay concentration) and tested at the same range of calcium concentrations in the presence of PAD4 (at the calculated Kd for each calcium condition) and 10 nM GSK215 in the same assay buffer and volume. Reactions are incubated for 50 min after which IC50 values are calculated using a four-parameter logistic equation [1]. |
| 動物實驗 | The study includes the MMTV-PyMT mouse model for mammary carcinoma (FVB/n background) and the RIP1-Tag2 mouse model for pancreatic neuroendocrine carcinoma (C57BL/6 background). Mice are treated daily by intra-peritoneal injections of the PAD4 inhibitor GSK484 (4 mg/kg). GSK484 is dissolved in 99.9% ethanol at a concentration of 25 mg/mL to generate a stock solution and further diluted 1:50 in 0.9% NaCl shortly before injection of 200 μL/mouse [2]. |
| 體外活性 | 方法：GSK484 hydrochloride (GTPL8577) （10μM）處理小鼠和人中性粒細胞，通過 Western blot 和新型成像測定證明了用鈣離子載體或細菌刺激的中性粒細胞對瓜氨酸化的抑制，并進一步研究對小鼠和人中性粒細胞體外 NET 形成的影響。
結果：GSK484 hydrochloride 預處理可顯著減少瓜氨酸生成和 NET 形成。[1] |
| 體內活性 | To address whether PAD4 inhibition can suppress cancer-associated kidney injury, MMTV-PyMT mice are treated with the PAD4 inhibitor GSK484 at 4 mg/kg daily for one week. This dose suppresses the elevated number of neutrophils undergoing NETosis in peripheral blood in mice with cancer. In parallel, the total protein level in urine from MMTV-PyMT mice is significantly reduced compared with untreated tumor-bearing mice. Administration of GSK484 at a dose of 4 mg/kg daily during one week reverts signs of kidney dysfunction in tumor-bearing mice to the same extent as DNase I treatment, without any detectable signs of toxicity [2]. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : 100 mg/mL (196.07 mM), Sonication is recommended.
PBS : <1 mg/mL (insoluble or slightly soluble)
DMSO : 45 mg/mL (88.23 mM), Sonication is recommended.
|
| 關鍵字 | GSK484 hydrochloride | GSK 484 | Protein Arginine Deiminase | GTPL-8577 | GSK484 Hydrochloride | GTPL 8577 | GSK-484 | AOB-6992 | GSK-484 hydrochloride | GSK484 | inhibit | Peptidylarginine Deiminase | GSK 484 Hydrochloride | AOB 6992 | Inhibitor | GSK-484 Hydrochloride |
| 相關產品 | BMS-P5 | BMS-P5 free base | GSK199 | Bongkrekic acid | Acefylline | GSK121 | N-[1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]benzamide | Cl-amidine hydrochloride |
| 相關庫 | 抑制劑庫 | 經典已知活性庫 | 已知活性化合物庫 | NO PAINS 化合物庫 | 表觀遺傳庫 |